Don't miss

Replay


LATEST SHOWS

EYE ON AFRICA

Amnesty accuses Sudan of chemical attacks on civilians

Read more

EYE ON AFRICA

Nations vote to end all trade of endangered pangolins

Read more

MEDIAWATCH

Trump accuses Google of 'suppressing bad news about Clinton'

Read more

THE DEBATE

What's the deal with oil? Saudi Arabia's about-face on OPEC (part 2)

Read more

THE DEBATE

What's the deal with oil? Saudi Arabia's about-face on OPEC (part 1)

Read more

BUSINESS DAILY

Dublin courts post-Brexit business

Read more

FOCUS

Afghanistan's national unity government faces political deadlock

Read more

REPORTERS

World War I: When northern France was on German time

Read more

INSIDE THE AMERICAS

Mixed reactions to historic Colombia peace deal

Read more

Cancer drug may help avert transplant rejection

Latest update : 2008-12-27

The bortezomib, a cancer treatment drug, has been tested successfully on several patients whose bodies had been rejecting transplanted organs, an American study found, concluding to "significant implications for transplantation."

AFP - A drug used to treat cancer has proven effective at stopping the body from rejecting a transplanted organ when other treatments failed, a study published Saturday found.
  
US researchers administered the drug, bortezomib, to six patients whose immune systems were attacking transplanted kidneys and who did not respond to traditional anti-rejection treatments.
  
In each case, the drug promptly reversed the rejection, improved organ function, provided prolonged reductions in antibody levels and suppressed recurrent rejection for at least five months.
  
"This has significant implications for transplantation and auto immune disease," said study co-author Steve Woodle, chief of transplant surgery at the University of Cincinnati in Ohio.
  
Woodle's team is currently conducting four clinical trials to expand upon these preliminary findings.
  
The drug's side effects proved to be both predictable and manageable and toxicity levels were much less than those associated with other anti-cancer agents, the study found.
  
"We are pleased to see its toxicities are similar in transplant recipients suffering from treatment-resistant mixed organ rejection," said study co-author Jason Everly, an oncology pharmacist at the University of Cincinnati.
  
"We hope it will be a viable therapeutic treatment option in this patient group."
  
Previous studies had found that B-cells play a large role in organ rejection by making immune proteins that attack transplants.
  
The drug targets these antibody-producing plasma cells and had been shown to suppress transplant rejection in the laboratory before Woodle and his team tested it on patients.
  
The study was published in the journal Transplantation.

Date created : 2008-12-27

COMMENT(S)